The effect of complex therapy on the quality of life in patients with arterial hypertension on the background of gout

Keywords: gout, arterial hypertension, quality of life, antihypertensive drugs, urate-lowering therapy


Abstract. Gout remains the most common type of inflammatory arthritis worldwide. Hypertension (AH) prevails in the structure of comorbid diseases in gout. In patients with hypertension in combination with gout, the problem of choosing treatment tactics remains quite relevant. Aim. To assess the effectiveness of the combination of basic therapy drugs for the treatment of patients with hypertension in combination with gout on quality of life indicators at the primary level of medical care. Materials and methods. Two groups of patients were formed. The first group, 36 patients who received losartan, allopurinol, atorvastatin. The second group, 36 people who received ramipril, allopurinol, atorvastatin. Quality of life was assessed using the SF-36 standardized questionnaire. The patient's functional status was assessed using the HAQ-DI health status questionnaire. Statistical analysis was performed using Statistica 6.1. Results. In the studied groups of patients, the quality of life of patients before and after treatment was evaluated. It was established that before the appointment of treatment, no significant difference was found between the groups according to the SF-36, HAQ-DI questionnaires. In patients of both groups, the indicators of the physical component of health (PCH) and the psychological component of health (PsCH) on the SF-36 scale were reduced, and a greater proportion of patients with minimal and moderate impairment of vital activity according to the HAQ-DI was registered. According to the results of the analysis, it was established that the level of quality of life according to the PCH indicator increased by 21.7 % in the first group and by 20.4 % in the second group (p < 0.01), according to the PsCH indicator – by 18.4 % and 17.5 % (p < 0.01), respectively. A probable decrease in the HAQ-DI indicator was found only in patients who received ramipril compared to the initial data before treatment by 33.3 % (р < 0.05). In patients of the I group, the share of patients with minimal disorders is increasing, and the proportion of patients with moderate disorders is decreasing, and in the II group, the prevalence of minimal and moderate disorders is increasing, which indicates the effectiveness of the prescribed therapy. Conclusions. Complex therapy (losartan or ramipril, allopurinol, atorvastatin) for 6 months in patients with hypertension in combination with gout is accompanied by a significant improvement in the quality of life according to the indicators of PCH (25.1 %, p < 0.01) and PsCH (17.7 %, p < 0.01) and degree of vital activity (25.0 %, p < 0.01).


Download data is not yet available.

Author Biographies

Ganna Kuzmina, Dnipro State Medical University

MD, PhD, professor of the department of therapy, cardiology and family medicine of postgraduate education Dnipro State Medical University, 2, 30-ty richchia Peremohy sq., Kryvyi Rih, Dnipropetrovsk region, Ukraine, 50056

Ольга Лазаренко, Дніпровський державний медичний університет

д-р філософії, асистент кафедри терапії, кардіології та сімейної медицини факультету післядипломної освіти, Дніпровський державний медичний університет, майдан 30-річчя Перемоги, 2, Кривий Ріг, Україна, 50056


Roddy E, Packham J, Obrenovic K, Rivett A, Ledingham JM. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. Rheumatology (Oxford). 2018 May 1;57(5):826-30. doi: 10.1093/rheumatology/kex521.

Bevis M, Blagojevic-Bucknall M, Mallen C, Hider S, Roddy E. Comorbidity clusters in people with gout: an observational cohort study with linked medical record review. Rheumatology (Oxford). 2018 Aug 1;57(8):1358–63. DOI:

Braun J, Kiltz U. What is new on gout? Report from ACR 2018. Z Rheumatol. 2019 Aug;78(6):540–9. DOI:

Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019 Jun;71(6):991-9. DOI:

Mattiuzzi C, Lippi G. Recent updates on worldwide gout epidemiology. Clin Rheumatol. 2019 Dec 13. DOI:

Malta DC, Goncalves RPF, Machado IE, Freitas MIF, Azeredo C, Szwarcwald CL. Prevalence of arterial hypertension according to different diagnostic criteria, National Health Survey. Rev Bras Epidemiol. 2018 Nov 29;21(suppl 1):e180021. DOI:

Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2018 Mar;129:95–9. DOI:

Mohsen IM. Hypertension in Developing Countries: A Major Challenge for the Future. Curr Hypertens Rep. 2018 May 1;20(5):38. DOI:

Sutton Burke EM, Kelly TC, Shoales LA, Nagel AK. Angiotensin Receptor Blockers Effect on Serum Uric Acid – A Class Effect? J Pharm Pract. 2019 Aug 7:897190019866315. DOI:

Park YA, Song YB, Yee J, Yoon HY, Gwak HS. Influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite E-3174: a systematic review and meta-analysis. J Pers Med. 2021;11(7):617. DOI:

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29–42. DOI:

Evans PL, Prior JA, Belcher J, Hay CA, Mallen CD, Roddy Е. Gender-specific risk factors for gout: a systematic review of cohort studies. Advances in Rheumatology. 2019 Jun 24;59(1):24. DOI:

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. DOI:

Janssens HJEM, Fransen J, Janssen M, Neogi T, Schumacher HR, Jansen TL, et al. Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population presenting with monoarthritis. Rheumatology (Oxford). 2017 Aug 1;56(8):1335–41. DOI:


Ashcroft JA. Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease. BMJ. 2018 Sep 20;362:k3895. DOI:

Keller SF, Rai SK, Lu N, Oza A, Jorge AM, Zhang Y, et al. Statin use and mortality in gout: A general population-based cohort study. Semin Arthritis Rheum. 2018 Dec;48(3):449–55. DOI:


How to Cite
Kuzmina, G., & Лазаренко, О. (2023). The effect of complex therapy on the quality of life in patients with arterial hypertension on the background of gout. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine&quot;, (47), 47-56.